Published on in Vol 9 (2023)

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/44339, first published .
Factors Associated With Online Patient-Provider Communications Among Cancer Survivors in the United States During COVID-19: Cross-sectional Study

Factors Associated With Online Patient-Provider Communications Among Cancer Survivors in the United States During COVID-19: Cross-sectional Study

Factors Associated With Online Patient-Provider Communications Among Cancer Survivors in the United States During COVID-19: Cross-sectional Study

Original Paper

1Department of Public Health Sciences, School of Medicine, University of California, Davis, Davis, CA, United States

2Stanford Center for Digital Health, Stanford Medicine, Stanford, CA, United States

3Program for Clinical Research & Technology, Department of Dermatology, School of Medicine, Stanford University, Stanford, CA, United States

4Health Management and Education, UC Davis Health Cardiac Rehabilitation, Davis, CA, United States

5Division of Health Policy and Management, Department of Public Health Sciences, University of California, Davis, Davis, CA, United States

6Division of Health Policy and Management, Department of Public Health Sciences, Center for Healthcare Policy and Research, University of California, Davis, Davis, CA, United States

7Division of Hematology and Oncology, UC Davis Comprehensive Cancer Center, Sacramento, CA, United States

Corresponding Author:

Jiyeong Kim, BPharm, MPH, PhD

Department of Public Health Sciences

School of Medicine

University of California, Davis

1 Shield ave

Davis, CA, 95616

United States

Phone: 1 5307522793

Email: jykim3@stanford.edu


Background: Online patient-provider communication (OPPC) is crucial in enhancing access to health information, self-care, and related health outcomes among cancer survivors. The necessity of OPPC increased during SARS-CoV-2/COVID-19, yet investigations in vulnerable subgroups have been limited.

Objective: This study aims to assess the prevalence of OPPC and sociodemographic and clinical characteristics associated with OPPC among cancer survivors and adults without a history of cancer during COVID-19 versus pre–COVID-19.

Methods: Nationally representative cross-sectional survey data (Health Information National Trends Survey 5, 2017-2020) were used among cancer survivors (N=1900) and adults without a history of cancer (N=13,292). COVID-19 data included data from February to June 2020. We calculated the prevalence of 3 types of OPPC, defined as using the email/internet, tablet/smartphone, or electronic health record (EHR) for patient-provider communication, in the past 12 months. To investigate the associations of sociodemographic and clinical factors with OPPC, multivariable-adjusted weighted logistic regression was performed to obtain odds ratios (ORs) and 95% CIs.

Results: The average prevalence of OPPC increased from pre-COVID to COVID among cancer survivors (39.7% vs 49.7%, email/internet; 32.2% vs 37.9%, tablet/smartphone; 19.0% vs 30.0%, EHR). Cancer survivors (OR 1.32, 95% CI 1.06-1.63) were slightly more likely to use email/internet communications than adults without a history of cancer prior to COVID-19. Among cancer survivors, the email/internet (OR 1.61, 95% CI 1.08-2.40) and EHRs (OR 1.92, 95% CI 1.22-3.02) were more likely to be used during COVID-19 than pre–COVID-19. During COVID-19, subgroups of cancer survivors, including Hispanics (OR 0.26, 95% CI 0.09-0.71 vs non-Hispanic Whites) or those with the lowest income (US $50,000-<US $75,000: OR 6.14, 95% CI 1.99-18.92; ≥US $75,000: OR 0.42, 95% CI 1.56-11.28 vs <US $20,000), with no usual source of care (OR 6.17, 95% CI 2.12-17.99), or reporting depression (OR 0.33, 95% CI 0.14-0.78) were less likely to use email/internet, and those who were the oldest (age 35-49 years: OR 9.33, 95% CI 2.18-40.01; age 50-64 years: OR 3.58, 95% CI 1.20-10.70; age 65-74 years: OR 3.09, 95% CI 1.09-8.76 vs age≥75 years), were unmarried (OR 2.26, 95% CI 1.06-4.86), or had public/no health insurance (Medicare, Medicaid, or other: ORs 0.19-0.21 vs private) were less likely to use a tablet/smartphone to communicate with providers. Cancer survivors with a usual source of care (OR 6.23, 95% CI 1.66-23.39) or health care office visits in a year (ORs 7.55-8.25) were significantly more likely to use EHRs to communicate. Although it was not observed in cancer survivors, a lower education level was associated with lower OPPC among adults without a history of cancer during COVID-19.

Conclusions: Our findings identified vulnerable subgroups of cancer survivors who were left behind in OPPC, which is increasingly becoming part of health care. These vulnerable subgroups of cancer survivors with lower OPPC should be helped through multidimensional interventions to prevent further inequities.

JMIR Cancer 2023;9:e44339

doi:10.2196/44339

Keywords



Online patient-provider communication (OPPC) refers to using online tools, including email/internet, tablets/smartphones, and mobile apps, for patient-provider communication [1]. Patient-provider communication is an essential element of cancer care and is associated with improved disease management, treatment adherence and quality, better health outcomes (eg, reduced mortality and mental distress), and superior health-related quality of life among cancer survivors [2-6]. Optimal OPPC has been found to have comparable benefits to face-to-face patient-provider communications among cancer survivors [7]. In addition, further benefits of OPPC among cancer survivors include increased access to health information, enhanced self-care ability, and an increased chance to be involved in health-related decision-making [8-10].

During the SARS-CoV-2/COVID-19 pandemic, the prevalence of poor mental health increased among cancer survivors [11-14]. Cancer survivors may have experienced a higher level of stress, fear, and psychological distress (eg, nervousness, worrying) due to delayed cancer care, fear of COVID-19 infection and poor health outcomes, or worry for cancer progression during COVID-19 than those without cancer [11,15-17]. Their unique situations would have required timely care and active communications with health providers to address health concerns and discuss care plans. Online-based health care became widely available in various health sectors during the early pandemic when in-person clinic visits were extremely limited owing to the pandemic [18-26]. Moreover, online-based care and communications will likely remain postpandemic for those who have medical conditions, because it became a major part of health care during the pandemic [27].

However, we do not know much about the adoption of online-based communications among cancer survivors during the early COVID-19 pandemic, although internet or digital device use behaviors in general US populations were assessed [28]. Given that OPPC use could also be a proxy of online-based care (eg, telehealth), which is only starting to be reported in some populations (eg, Medicare beneficiaries) [29,30], it is important to investigate subgroups who had low OPPC practice.

Previously, few studies have identified subgroups of cancer survivors who were vulnerable to OPPC before COVID-19 [7,31,32] and none, to the best of our knowledge, during the pandemic.

Before the COVID-19 pandemic, the adoption of and access to technology-based communication with providers was found to differ by some socioeconomic characteristics among cancer survivors. In a study by Jiang et al [7] using the national survey data (Health Information National Trends Survey [HINTS] 2008-2017), income, education, age, and health status were associated with OPPC via email, mobile platforms, and electronic health records (EHRs) among cancer survivors, yet the associations were inconsistent by year [7]. Two other studies, using HINTS (2003-2008 [31] and 2003-2018 [32]), found that young, highly educated, and metropolitan cancer survivors were more likely to email health care professionals. However, knowledge gaps still exist in OPPC practice among cancer survivors during COVID-19 compared to pre–COVID-19. Moreover, no studies have compared OPPC use in cancer survivors to the general population in prevalence and associations. Therefore, this study aimed to evaluate whether OPPC was higher among cancer survivors during COVID-19 than pre–COVID-19 and identify subgroups of cancer survivors with lower adoption of OPPC compared to those without a history of cancer during COVID-19.


Data Source

This study used nationally representative survey data from HINTS [33]. HINTS contains publicly available, self-administered, cross-sectional data collected by the National Cancer Institute (NCI). HINTS 5 Cycles 1-4 data from 2017 to 2020 were used for this study. HINTS 5 Cycles 1, 2, and 4 are single-mode mailed surveys that used a 2-stage sampling design, while HINTS 5 Cycle 3 is a double-mode design with a pilot push-to web survey in addition to the mailed survey. Remediated HINTS 5 Cycle 3 data were released in March 2021, and this study used the updated data. The survey questionnaires were distributed to noninstitutionalized civilians aged 18 years and older in the United States. HINTS 5 applied 2 stratified geographic addresses with areas of a high concentration of minority populations or a low concentration of minority populations, except for HINTS 5 Cycle 1. Cycle 1 used 3 stratified geographic addresses, adding the counties of Central Appalachia. The study followed Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines [34]. The total number of survey respondents in HINTS 5 Cycles 1-4 was 16,092, and the 4-year average response rate was approximately 33.0% (n=3285, 32.4%, in Cycle 1; n=3504, 32.4%, in Cycle 2; n=5438, 30.3%, in Cycle 3; n=3865, 36.7%, in Cycle 4) [35]. Because we needed to combine the data from 4 survey cycles, we evaluated differences in variables across the cycles and the survey mode (mailed, push-to-web with paper return, push-to-web with web return) prior to merging the data. Because no critical discrepancies were identified in the variables of our interest by cycle, we merged the data from the 4 cycles, following the recommended analytic process provided by HINTS. We obtained 200 replicate weights, which were used to calculate SEs. Full sampling weights were applied for the sample to be nationally representative. The full sampling weight is intended to account for household-level base weight, nonresponse, person-level initial weight, and other biases [36]. Among the total respondents, excluding those who missed questions on a history of cancer (n=221, 1.4%), those who reported that they had ever been diagnosed with cancer were considered as cancer survivors after further excluding those with nonmelanoma skin cancer (N=1900) and the remaining (N=13,292) were considered as adults without a history of cancer.

Outcomes

OPPC was measured using 3 types of communication behaviors, including the email/internet, tablet/smartphone, and EHR, as described previously [7]. Although the 3 types of OPPC might not be mutually exclusive, we used the following questions to measure different types and levels of participants’ behaviors in technology-based patient-provider communications: (1) “In the past 12 months, have you used email or the internet to communicate with a doctor or doctor's office?,” which required a basic level of technology literacy (email) and a technology-enabling environment (internet connection); (2) “Has your tablet or smartphone helped you in discussions with your health care provider?,” which demanded an advanced level of technology literacy (eg, live chatting, video visits) and digital device ownership (tablet, smartphone); and (3) “In the past 12 months, have you used your online medical record to securely message health care providers and staff?,” which additionally required some degree of engagement with the health care system. The responses were either yes or no, and those who answered yes were considered as practicing OPPC. The tablet/smartphone and EHR questions were only asked to those who owned tablet computers/smartphones or had used EHRs at least once in the past 12 months. In this study, those who did not have a tablet/smartphone or did not use EHRs once in the past 12 months were included in the no-OPPC groups using a tablet/smartphone or EHRs, respectively.

Covariates

Sociodemographic Characteristics

We used the social determinants of the health conceptual framework from Healthy People 2030 [37] to choose sociodemographic factors as independent variables in this study: age (18-34, 35-49, 50-64, 65-74, ≥75 years), birth gender (male, female), race/ethnicity (non-Hispanic White, non-Hispanic Black/African American, Hispanic, non-Hispanic Asian, other), household income (<US $20,000, US $20,000-<US $35,000, US $35,000-<US $50,000, US $50,000-<US $75,000, ≥US $75,000), educational attainment (less than high school, high school graduate, some college, college graduate or more), marital status (married or living with a romantic partner as married vs not married, including divorced, widowed, separated, single/never been married), employment status (employed vs unemployed, including homemaker, student, retired, disabled), health insurance type (insured by employment, private insurance, Medicaid, Medicare, Tricare, Veterans Affairs [VA], Indian Health Services [IHS]), a usual source of care (yes, no), number of health care office visits (0, 1-4, 5-9), and rurality of residence (metropolitan, micropolitan, small town, rural). HINTS used the Urban-Rural Commuting Area (RUCA), which categorizes census tracts based on population density, urbanization, and commuting patterns developed by the United States Department of Agriculture to determine the rurality of residence of the respondents [38].

Clinical Characteristics

Clinical characteristics included general health status (excellent/very good/good, fair/poor), chronic medical conditions (diabetes, high blood pressure, heart disease, lung disease, depression), time since cancer diagnosis (<1 year, 2-5 years, 6-10 years, ≥11 years), psychological distress (little interest, hopelessness, nervousness, worrying), and cancer type the respondents were diagnosed with (breast, cervical, prostate, colon, lung, melanoma, bladder, bone, endometrial, head and neck, leukemia/blood, liver, lymphoma [Hodgkin and non-Hodgkin], oral, ovarian, pancreatic, pharyngeal, rectal, renal, stomach, multiple cancers). We recoded unknown and less prevalent cancer types, including bladder, bone, endometrial, head and neck, leukemia/blood, liver, lymphoma, oral, ovarian, pancreatic, pharyngeal, rectal, renal, and stomach cancer, as “other.”

Statistical Analysis

We conducted survey-weighted descriptive analyses to demonstrate the sociodemographic and clinical characteristics of cancer survivors with frequency (n) and weighted percentage (%) during the COVID-19 (HINTS 5 Cycle 4, 2020) and pre–COVID-19 (HINTS 5 Cycles 1-3, 2017-2019) periods. Of note, the Cycle 4 questionnaires were collected from February to June 2020. Survey-weighted descriptive analyses were also performed to report the prevalence of 3 OPPC outcomes by sociodemographic and clinical factors among cancer survivors pre–COVID-19 and during COVID-19. We used multivariable-adjusted weighted logistic regression to obtain odds ratios (ORs) and associated 95% CIs to examine the associations of sociodemographic factors and clinical predictors with each OPPC outcome. The psychological distress measurements were converted to depression (little interest and hopelessness) or anxiety (nervousness and worrying) symptoms using the Patient Health Questionnaire-2 (PHQ-2) or General Anxiety Disorder-2 (GAD-2) scales, respectively, following their clinical cutoff (score≥3: symptom presents) [39]. Cancer survivors and adults without a history of cancer were analyzed in a model to compare the association of being a cancer survivor on each OPPC outcome after controlling for age, race/ethnicity, education, income, marital status, health insurance type, having a usual source of care, number of office visits, general health condition, chronic health condition (depression), and mental health (depression or anxiety symptoms). Because being a cancer survivor was associated with OPPC outcomes (email/internet use to communicate with providers, P=.035), we stratified cancer survivors and adults without a history of cancer to investigate the associations with sociodemographic and clinical factors. We developed 6 multivariable-adjusted weighted logistic regression models for 3 OPPC outcomes during COVID-19 and pre–COVID-19 among cancer survivors. Separately, 6 models were developed for adults without a history of cancer (Multimedia Appendix 1). Sociodemographic and clinical variables were included in a final model only if they were significantly associated with the outcome in univariable analyses (P<.05) or if they were considered a confounder for another covariate (eg, when the covariate effect estimate changed by more than 10%). Employment status was not reported in HINTS 5 Cycle 3, so it was not included in the models due to a huge portion of data unavailability (35.0%). For other covariates, the range of missingness varied from 0% to 13.3%, yet it was mostly less than 4.5%. To account for these missing data, which were considered suitable to impute, we applied a hot deck imputation method, which HINTS used to account for the nonresponse [36]. Adjustments for multiple testing were not performed, because this study was not confirmatory by design and we intended to avoid the potential risk of increasing type II errors [40,41]. Statistical significance was determined at P<.05 using SAS 9.4 (SAS Studio).

Ethical Considerations

This study used the publicly available national survey data (HINTS). The study was a secondary analysis of survey data; human subjects were not involved, and identifiable information was not included. Given that the data were deidentified, the study was deemed exempt from review by the Institutional Review Board of the University of California, Davis.


Description of Cancer Survivors

Of 1900 cancer survivors, 1444 (76.0%) were surveyed pre–COVID-19 (2017-2019) and 456 (24.0%) were surveyed during the COVID-19 pandemic (2020). There were no significant differences between the characteristics of the cancer survivors during the pre–COVID-19 and COVID-19 periods (Tables 1 and 2). Nearly half (n=289, 48.0%) were aged 65 years or older, 59.0% (n=272) were female, 79.0% (n=329) were non-Hispanic White, 63.0% (n=313) had some college education or more, 63.0% (n=228) were married, 62.0% (n=338) had public/government-aided health insurance, 84.0% (n=392) had a usual source of care, and 91.0% (n=420) had health care office visits at least once in a year. Clinically, 73.0% (n=322) reported that their general health status was good, while 56.0% (n=283) reported high blood pressure, 28.0% (n=149) had diabetes, 24.0% (n=111) had depression, and 12.0% (n=62) and 13.0% (n=60) reported that they had depressive and anxiety symptoms in the past 2 weeks, respectively. Nearly half of the cancer survivors (n=211, 46.0%) were 11 years or more from cancer diagnosis (Tables 1 and 2).

Table 1. Sociodemographic characteristics of cancer survivors (N=1900) pre–COVID-19 (2017-2019; HINTSa 5 Cycles 1-3) and during COVID-19 (2020; HINTS 5 Cycle 4).
CharacteristicsPre–COVID-19b (n=1444)cDuring COVID-19b (n=456)c


Frequency, n (%)SE for weighted percentageFrequency, n (%)SE for weighted percentage
Age (years)

18-3422 (5.7)2.09 (2.3)0.8

35-4999 (11.8)1.631 (17.5)3.7

50-64412 (31.8)1.9127 (32.8)4.0

65-74477 (25.5)1.6155 (25.5)2.6

≥75434 (25.2)1.6134 (22.0)2.3
Gender

Female875 (59.5)2.0272 (58.8)4.0

Male569 (40.5)2.0184 (41.2)4.0
Race/ethnicity

Non-Hispanic White1057 (73.8)2.0329 (79.3)2.6

Non-Hispanic Black/African American179 (11.0)1.753 (8.3)1.5

Hispanic120 (10.2)1.553 (9.0)2.2

Non-Hispanic Asian33 (2.0)0.510 (1.5)0.6

Other55 (3.1)0.711 (1.8)1.0
Education

Less than high school88 (7.5)1.639 (7.0)1.7

High school315 (26.9)2.0104 (30.0)3.1

Some college481 (40.1)2.0137 (39.9)3.3

College graduate or more560 (25.6)1.5176 (23.1)2.9
Household income (US $)

<20,000284 (16.9)1.7100 (21.9)3.0

20,000-<35,000242 (15.9)1.473 (12.5)2.2

35,000-<50,000194 (14.9)2.372 (16.3)2.6

50,000-<75,000285 (19.4)1.778 (19.0)3.1

≥75,000439 (32.8)2.0133 (30.2)2.9
Employmentd

Employed228 (36.2)2.5126 (34.8)3.7

Unemployed535 (63.8)2.5328 (65.2)3.7
Marital status

Married729 (59.6)2.1228 (63.3)3.4

Not married715 (40.4)2.1228 (36.7)3.4
Rurality

Metropolitan1221 (83.6)1.5386 (78.7)2.6

Micropolitan127 (9.9)1.233 (10.9)2.6

Small town56 (3.1)0.618 (5.6)2.1

Rural40 (3.4)0.719 (4.7)1.5
Health insurance type

Employment/private359 (31.6)2.1118 (37.9)3.7

Medicare570 (31.9)1.7179 (32.4)2.9

Medicaid174 (16.6)2.270 (16.7)2.5

Tricare, VAe, IHSf173 (9.9)1.240 (4.9)1.1

Other168 (10.1)1.049 (8.0)2.1
Usual source of care

Yes1205 (82.9)1.4392 (83.7)3.2

No239 (17.1)1.464 (16.3)3.2
Number of office visits in a year

086 (7.4)1.336 (9.5)2.7

1-4791 (56.9)2.5234 (50.6)4.0

5-9567 (35.8)2.2186 (39.9)3.7

aHINTS: Health Information National Trends Survey.

bMissingness of covariates: pre–COVID-19 (age 2.1 %, gender 1.0%, race/ethnicity 11.9%, education 1.5%, income 13.0%, marital status 1.7%, health insurance type 4.4%, usual source of care 1.8%, general health status 1.5%, diabetes 2.8%, high blood pressure 2.4%, heart disease 1.6%, lung disease 1.7%, depression 2.6%, time since diagnosis 4.8%, cancer type 1.9%) and during COVID-19 (age 1.3 %, gender 0.7%, race/ethnicity 12.5%, education 3.9%, income 11.0%, marital status 2.9%, health insurance type 3.7%, usual source of care 3.3%, general health status 0.7%, diabetes 1.8%, high blood pressure 1.3%, heart disease 1.5%, lung disease 1.8%, depression 1.3, time since diagnosis 4.4%, cancer type 3.5%).

cCovariates with any missing values were imputed in the table.

dEmployment data were not reported in Cycle 3; n=681 (35.8%) unavailable.

eVA: Veterans Affairs.

fIHS: Indian Health Services.

Table 2. Clinical characteristics of cancer survivors (N=1900) pre–COVID-19 (2017-2019; HINTSa 5 Cycles 1-3) and during COVID-19 (2020; HINTS 5 Cycle 4).
CharacteristicsPre–COVID-19b (n=1444)cDuring COVID-19b (n=456)c


Frequency, n (%)SE for weighted percentageFrequency, n (%)SE for weighted percentage
General health status

Excellent/good1073 (72.6)1.9322 (73.1)3.0

Fair/poor371 (27.4)1.9134 (26.9)3.0
Chronic medical condition(ever told)

Diabetes415 (24.9)1.8149 (27.7)3.0

High blood pressure860 (54.5)2.1283 (55.5)3.5

Heart disease248 (15.6)1.566 (11.6)1.9

Lung disease243 (16.1)1.2106 (20.2)2.9

Depression332 (22.7)1.7111 (24.0)2.8
Mental health (past 2 weeks)

Depression symptoms203 (16.0)1.962 (11.6)2.0

Anxiety symptoms168 (12.6)1.460 (13.4)2.2
Time since diagnosis (years)

<1177 (13.3)1.567 (16.1)3.1

2-5313 (21.5)1.887 (18.2)2.9

6-10268 (16.6)1.491 (19.6)2.4

≥11686 (48.7)2.0211 (46.0)3.7
Cancer type

Breast282 (17.0)1.488 (19.2)3.3

Cervical96 (8.9)1.436 (9.4)2.5

Prostate173 (8.6)1.061 (8.8)1.5

Colon80 (5.4)0.926 (4.6)0.9

Lung37 (2.8)0.612 (1.3)0.5

Melanoma85 (5.1)0.933 (10.9)2.6

Multiple348 (23.7)1.690 (17.4)2.4

Other343 (28.5)2.4110 (28.4)3.5

aHINTS: Health Information National Trends Survey.

bMissingness of covariates: pre–COVID-19 (age 2.1 %, gender 1.0%, race/ethnicity 11.9%, education 1.5%, income 13.0%, marital status 1.7%, health insurance type 4.4%, usual source of care 1.8%, general health status 1.5%, diabetes 2.8%, high blood pressure 2.4%, heart disease 1.6%, lung disease 1.7%, depression 2.6%, time since diagnosis 4.8%, cancer type 1.9%) and during COVID-19 (age 1.3 %, gender 0.7%, race/ethnicity 12.5%, education 3.9%, income 11.0%, marital status 2.9%, health insurance type 3.7%, usual source of care 3.3%, general health status 0.7%, diabetes 1.8%, high blood pressure 1.3%, heart disease 1.5%, lung disease 1.8%, depression 1.3, time since diagnosis 4.4%, cancer type 3.5%).

cCovariates with any missing values were imputed in the table.

Prevalence of OPPC Among Cancer Survivors Compared to Adults Without a History of Cancer

The average prevalence of OPPC increased pre–COVID-19 to COVID-19 among cancer survivors: from 39.7% to 49.7% for email/internet use for communications with the provider/office, from 32.2% to 37.9% for tablet/smartphone use for discussions with providers, and from 19.0% to 30.0% for EHR use for messaging providers pre–COVID-19; see Figure 1. The average prevalence of OPPC among cancer survivors was similar to that among adults without a history of cancer pre–COVID-19 (approximate percentage, averaging out 3 OPPCs=29.0%) but was higher among cancer survivors during COVID-19. In multivariable models, cancer survivors were approximately 1.3 times as likely to use email/internet pre–COVID-19 than adults without a history of cancer (Table 3).

Figure 1. Prevalence of OPPC use. Pre–COVID-19 (2017-2019) and during COVID-19 (2020). The prevalence of OPPC use was presented as a weighted percentage. Cancer survivors (N=1900) and US adults without a history of cancer (N=13,292). EHR: electronic health record; OPPC: online patient-provider communication; smartp: smartphone.
Table 3. Associations of a history of cancer with OPPCa outcomes.
History of cancerPre–COVID-19b (2017-2019; N=11,351), aORc,d (95% CI)During COVID-19b (2020), aORd (95% CI)

Email/internet (n=11,351)Tablet/smartphone (n=10,759)EHRe (n=9751)Email/internet (n=3568)Tablet/smartphone (n=3554)EHR (n=3541)
Yes1.32 (1.06-1.63)f1.21 (0.95-1.54)0.98 (0.78-1.23)1.28 (0.87-1.88)1.20 (0.86-1.70)1.39 (0.92-2.12)
NoReferenceReferenceReferenceReferenceReferenceReference

aOPPC: online patient-provider communication.

bTotal sample size: pre–COVID-19 (N=11,718) and during COVID-19 (N=3695).

caOR: adjusted odds ratio.

dAdjusted by age, race/ethnicity, education, income, marital status, health insurance type, having a usual source of care, number of office visits, general health condition, chronic medical condition (depression), and mental health (depression or anxiety symptoms).

eEHR: electronic health record.

fP<.05.

Prevalence of OPPC by Sociodemographic and Clinical Factors Pre–COVID-19 and During COVID-19

Tables 4 and 5 show the prevalence of OPPC by sociodemographic and clinical factors among cancer survivors before and during COVID-19. In general, cancer survivors who were younger than 65 years, were more educated (some college or more education), had a high income (US $50,000 or more), were married, were employed, were metropolitan residents, had private/employment-based insurance, had a usual source of care or health care office visits, had good general health status and chronic medical conditions (eg, depression), were recently diagnosed (<6 years) or diagnosed with breast cancer showed a high prevalence of OPPC than the average in both time periods. Although the prevalence of OPPC was similar between pre–COVID-19 and COVID-19 for most sociodemographic and clinical subgroups, there were some noticeable differences during COVID-19. Non-Hispanic White cancer survivors had higher-than- average prevalence in all 3 types of OPPC during COVID-19, while non-Hispanic Asians had higher OPPC before COVID-19.

Table 4. Prevalence of OPPCa by sociodemographic factors among cancer survivors.
CharacteristicsPre–COVID-19 (2017-2019), weighted percentage (SE)During COVID-19 (2020), weighted percentage (SE)


Email/internetTablet/smartphoneEHRbEmail/internetTablet/smartphoneEHR
Average prevalence (%)39.7 (2.2)32.2 (2.4)19.0 (1.6)49.7 (4.0)37.9 (4.1)30.0 (3.8)
Age (years)

18-3453.0 (21.8)c56.8 (22.1)c7.7 (5.2)67.8 (23.9)c40.6 (24.5)c6.3 (7.0)

35-4950.5 (6.4)c36.4 (7.4)c31.4 (6.1)c58.8 (13.9)c69.8 (13.2)c21.5 (9.3)

50-6446.4 (4.1)c35.7 (3.9)c19.9 (2.6)c57.2 (7.1)c50.0 (6.3)c45.3 (7.5)c

65-7439.1 (3.3)35.0 (3.2)c20.3 (2.8)c40.8 (5.2)23.7 (5.1)25.0 (4.9)

≥7523.2 (3.1)15.6 (2.5)12.9 (2.4)39.0 (6.6)9.9 (3.1)21.0 (6.6)
Gender

Female37.1 (2.6)29.7 (2.5)19.5 (2.1)c46.2 (6.0)41.6 (5.5)c27.2 (4.6)

Male43.6 (4.0)c35.8 (4.1)c18.4 (2.8)54.8 (4.5)c33.0 (6.3)34.0 (5.2)c
Race/ethnicity

Non-Hispanic White40.3 (2.2)c29.0 (2.1)20.6 (1.8)c53.5 (4.4)c38.3 (4.7)c31.4 (4.3)c

Non-Hispanic Black/African American44.5 (10.8)c43.9 (11.9)c10.7 (3.7)30.6 (7.8)27.8 (8.1)26.6 (7.9)

Hispanic28.7 (7.0)36.8 (8.4)c14.4 (6.7)35.2 (11.8)43.5 (10.8)c24.4 (11.6)

Non-Hispanic Asian50.2 (11.9)c50.3 (12.3)c36.5 (15.6)c35.0 (18.3)35.2 (18.7)18.1 (14.2)

Other38.8 (14.3)43.7 (15.6)c16.1 (7.8)59.6 (30.0)c47.8 (35.7)c17.2 (13.9)
Education

Less than high school29.9 (18.5)36.4 (20.0)c3.8 (3.0)30.2 (13.0)11.2 (6.3)20.9 (12.0)

High school25.8 (3.7)24.4 (4.0)11.8 (2.7)44.2 (7.9)37.2 (8.5)19.0 (6.6)

Some college42.5 (3.7)c33.8 (3.6)c17.2 (2.8)46.2 (6.6)38.7 (6.6)c28.8 (5.7)

College graduate or more52.4 (3.1)c36.2 (2.9)c32.7 (3.2)c69.8 (4.2)c46.1 (7.0)c50.0 (7.2)c
Household income (US $)

<20,00017.9 (3.2)20.4 (4.2)8.2 (2.1)27.7 (6.7)30.7 (8.8)16.0 (5.5)

20,000-<35,00029.4 (4.4)26.3 (4.7)15.2 (3.3)30.2 (9.3)21.5 (6.8)15.7 (4.8)

35,000-<50,00042.3 (7.2)c35.4 (10.6)c17.9 (5.0)48.7 (8.9)28.2 (6.6)28.5 (7.7)

50,000-<75,00044.6 (4.8)c37.7 (4.7)c20.8 (3.7)c65.1 (8.8)c45.9 (10.4)c29.3 (7.9)

≥75,00051.8 (3.5)c35.8 (3.7)c25.4 (3.0)c63.5 (7.1)c48.7 (7.4)c47.3 (8.5)c
Marital status

Married44.1 (2.4)c34.0 (2.7)c20.9 (2.1)c54.1 (5.2)c44.8 (5.5)c34.7 (5.5)c

Not married33.3 (4.0)29.5 (4.2)16.2 (2.4)42.0 (6.4)24.8 (4.2)21.6 (4.9)
Employment

Employed49.4 (4.8)c33.8 (4.8)c21.8 (4.0)c65.6 (7.4)c59.7 (6.8)c39.3 (8.0)c

Unemployed31.0 (3.3)31.0 (3.7)16.1 (2.7)41.1 (4.1)26.3 (4.6)24.9 (2.9)
Rurality

Metropolitan42.5 (2.4)c34.0 (2.6)c19.7 (1.9)c51.2 (4.5)c38.6 (4.5)c30.7 (4.0)c

Micropolitan28.0 (5.2)20.4 (5.5)16.9 (4.8)51.1 (14.7)35.2 (17.3)43.5 (16.4)

Small town26.6 (7.2)30.4 (8.7)14.7 (6.8)10.7 (10.9)34.5 (33.4)10.5 (11.8)

Rural16.2 (7.8)23.8 (9.7)12.7 (7.0)68.2 (18.0)c36.9 (19.5)8.5 (5.6)
Health insurance

Employment/private55.9 (4.2)c36.8 (4.2)c23.8 (3.1)c64.9 (7.3)c65.6 (6.0)c43.6 (8.0)c

Medicare34.2 (2.8)27.0 (2.7)20.5 (2.5)c39.2 (5.3)17.2 (3.7)22.6 (4.2)

Medicaid31.4 (8.9)37.5 (9.5)c13.4 (4.3)40.8 (10.7)26.0 (7.7)17.0 (6.8)

Tricare, VAd, IHSe29.0 (5.3)30.3 (5.2)13.4 (4.4)60.1 (12.9)c29.8 (9.3)32.0 (11.0)c

Other30.3 (4.5)26.7 (5.0)14.7 (3.9)35.1 (7.8)18.9 (4.9)23.2 (6.1)
Usual source of care

Yes42.3 (2.5)c34.8 (2.7)c20.9 (2.0)c53.6 (4.1)c37.8 (4.7)34.2 (4.0)c

No27.5 (4.5)20.0 (4.0)8.9 (2.4)26.6 (11.8)38.6 (14.9)c5.7 (2.9)
Number of office visits in a year

020.6 (6.6)10.7 (4.9)7.9 (6.3)43.9 (16.3)30.3 (19.5)3.9 (2.7)

1-439.8 (2.9)c30.5 (3.3)16.0 (2.0)47.7 (5.2)37.6 (6.1)31.9 (4.7)c

5-943.6 (3.4)c39.7 (3.7)c25.7 (3.1)c53.7 (6.7)c39.9 (6.8)c33.5 (5.6)c

aOPPC: online patient-provider communication.

bEHR: electronic health record.

cPrevalence is higher than the average.

dVA: Veterans Affairs.

eIHS: Indian Health Services.

Table 5. Prevalence of OPPCa by clinical factors among cancer survivors.
CharacteristicsPre–COVID-19 (2017-2019), weighted percentage (SE)During COVID-19 (2020), weighted percentage (SE)


Email/internetTablet/smartphoneEHRbEmail/internetTablet/smartphoneEHR
General healthstatus

Excellent/good42.6 (2.5)c30.9 (2.8)19.5 (2.0)c54.9 (4.5)c43.5 (4.5)c32.0 (4.4)c

Fair/poor31.9 (3.8)35.9 (4.4)c17.9 (3.0)35.4 (6.4)23.0 (5.4)24.7 (5.9)
Chronic condition (ever diagnosed)

Diabetes35.5 (4.0)29.1 (4.1)18.4 (3.3)47.7 (7.3)32.6 (6.9)32.5 (7.7)c

High blood pressure37.2 (2.6)30.7 (2.4)19.5 (2.2)c51.6 (4.4)c33.2 (5.7)33.1 (5.1)c

Heart disease36.7 (4.9)33.2 (5.1)c20.1 (4.3)c37.5 (8.4)27.6 (7.4)23.1 (6.3)

Lung disease32.9 (4.6)30.2 (4.9)18.2 (4.0)43.6 (6.2)33.6 (7.6)30.0 (5.6)

Depression44.4 (3.9)c38.1 (4.6)c23.9 (4.0)c38.4 (7.3)38.9 (7.5)c26.3 (5.9)
Mental health (past 2 weeks)

Depression symptoms41.2 (8.1)c38.3 (8.9)c15.7 (4.4)40.1 (9.3)27.3 (10.0)21.1 (7.8)

Anxiety symptoms42.3 (5.8)c36.0 (5.8)c20.4 (5.1)c46.0 (9.5)36.0 (9.7)28.4 (8.4)
Time since diagnosis (years)

<143.9 (6.2)c36.4 (6.6)c19.4 (4.9)c63.8 (10.2)c54.8 (12.1)c32.7 (10.1)c

2-549.5 (5.5)c43.7 (6.2)c25.0 (4.3)c47.2 (8.8)35.0 (8.6)30.2 (8.2)c

6-1039.4 (4.2)29.0 (3.9)22.5 (4.1)c38.9 (9.3)32.4 (9.4)19.0 (5.3)

≥1134.3 (3.1)27.0 (2.7)14.9 (2.1)50.3 (5.7)c35.3 (5.4)33.2 (5.9)c
Cancer type

Breast39.9 (4.0)c36.8 (4.5)c23.6 (3.9)c55.8 (9.1)c52.2 (9.1)c32.3 (8.1)c

Cervical41.7 (7.9)c31.1 (7.8)22.9 (7.0)c49.7 (16.4)39.4 (15.1)c27.2 (13.8)

Prostate34.1 (5.2)29.3 (4.9)12.6 (3.5)48.4 (11.3)18.9 (7.1)35.2 (10.3)c

Colon42.2 (10.9)c50.2 (11.2)c10.6 (8.1)45.0 (12.9)26.8 (10.7)24.6 (10.0)

Lung19.8 (8.5)11.2 (6.8)7.0 (3.6)38.2 (22.2)41.4 (21.5)c7.6 (6.3)

Melanoma45.5 (8.9)c20.8 (5.9)23.6 (7.9)c52.8 (14.1)c40.0 (17.0)c31.3 (14.0)c

Multiple43.0 (4.5)c31.5 (3.7)22.0 (3.5)c49.3 (9.7)20.8 (5.6)29.6 (7.8)

Other38.6 (5.2)32.4 (5.6)c16.5 (2.8)46.2 (8.2)45.0 (9.3)c29.3 (7.3)

aOPPC: online patient-provider communication.

bEHR: electronic health record.

cPrevalence is higher than the average.

Sociodemographic and Clinical Factors Associated With OPPC Among Cancer Survivors Pre–COVID-19 vs COVID-19

Email/internet and EHR-based communications were 1.5-2 times as likely to be used during COVID-19 than pre–COVID-19 (email/internet: OR 1.61, 95% CI 1.08-2.40; EHR: OR 1.92, 95% CI 1.22-3.02).

Pre–COVID-19, younger age groups (18-74 years old) had nearly 2-9 times the odds of using the email/internet, tablet/smartphone, or EHR to communicate with providers compared to those 75 years or older (Tables 6-8). Cancer survivors with a higher annual income (US $20,000 or more) were 2-3.5 times as likely to communicate electronically with providers via the email/internet, tablet/smartphone, or EHR than those with less than US $20,000 of income. Those insured by private or employment-based plans had 2 times the odds of using email/internet for communications than those with public/government-supported insurance (Medicaid, Tricare/VA/IHS, other: ORs 0.41-0.49). Those who were recently diagnosed with cancer (2-5 years) were nearly 2 times as likely to use the email/internet, tablet/smartphone, or EHR for communications with providers/offices as those diagnosed more than 10 years ago (OR 2.02, 95% CI 1.23-3.33; OR 1.86, 95% CI 1.14-3.03; and OR 2.30, 95% CI 1.29-4.11, respectively). Those with a usual source of health care had 2.5 times (OR 2.55, 95% CI 1.21-5.38) the odds of using EHRs, and those who had health care office visits at least once had 4-6 times (ORs 4.46-5.91) the odds of using a tablet/smartphone to communicate with providers compared to those without a usual source of care or office visits. Breast cancer survivors were more likely to use a tablet/smartphone and EHRs than lung cancer survivors to communicate with providers.

During COVID-19, cancer survivors with a usual source of care had 6 times the odds of using email/internet (OR 6.17, 95% CI 2.12-17.99) or EHRs (OR 6.23, 95% CI 1.66-23.39) to communicate with providers/offices (Tables 6-8). Moreover, those who had health care office visits at least once in a year were 8 times as likely to use EHRs to send messages to the provider (1-4 times: OR 8.25, 95% CI 1.61-42.18; 5-9 times: OR 7.55, 95% CI 1.56-36.60) than those without any office visits. Hispanic cancer survivors (OR 0.26, 95% CI 0.09-0.71) were significantly less likely to use email/internet to communicate with providers/offices than their non-Hispanic White counterparts. Cancer survivors with more income (≥US $50,000 vs <US $20,000) had 4-6 times the odds of using email/internet for communications with providers/offices. Cancer survivors reporting a history of depression diagnosis were less likely to use email/internet to communicate with providers/offices (OR 0.33, 95% CI 0.14-0.78). The oldest individuals (≥75 years) were significantly less likely to use a tablet/smartphone to discuss with providers than their younger counterparts (35-74 years: ORs 3.09-9.33). Married cancer survivors were 2 times as likely to use a tablet/smartphone for communications (OR 2.26, 95% CI 1.06-4.86). Cancer survivors insured by Medicare (OR 0.21, 95% CI 0.08-0.54), Medicaid (OR 0.19, 95% CI 0.06-0.61), or other types of health plans (OR 0.20, 95% CI 0.07-0.58) were significantly less likely to discuss with providers via a tablet/smartphone than those with private or employment-based insurance.

Table 6. Associations of time period with OPPCa among cancer survivors.
Time periodEmail/internet, aORb,c (95% CI)Tablet/smartphone, aORc (95% CI)EHRd, aORc (95% CI)
During COVID-19 (2000)1.61 (1.08-2.40)e1.40 (0.90-2.20)1.92 (1.22-3.02)e
Pre–COVID-19 (2017-2019)ReferenceReferenceReference

aOPPC: online patient-provider communication.

baOR: adjusted odds ratio.

cAdjusted for all the variables in the table.

dEHR: electronic health record.

eP<.05.

Table 7. Associations of sociodemographic factors with OPPCa among cancer survivors pre–COVID-19 (2017-2019) and during COVID-19 (2020).
FactorsPre–COVID-19 (N=1444), aORb,c (95% CI)During COVID-19 (N=456), aORc (95% CI)


Email/internet (n=1411)Tablet/smartphone (n=1307)EHRd (n=1229)Email/internet (n=446)Tablet/smartphone (n=441)EHR (n=444)
Age (years)

18-347.43 (2.47-22.29)e9.59 (3.03-30.35)e0.87 (0.21-3.65)5.38 (0.65-44.88)1.04 (0.03-39.71)0.40 (0.01-11.97)

35-492.52 (1.18-5.39)e2.85 (1.26-6.46)e2.52 (1.03-6.19)e3.53 (0.55-22.47)9.33 (2.18-40.01)e1.13 (0.18-7.14)

50-642.30 (1.30-4.06)e2.85 (1.62-5.01)e1.47 (0.69-3.11)1.74 (0.43-7.10)3.58 (1.20-10.70)e1.94 (0.38-9.82)

65-742.16 (1.36-3.43)e2.91 (1.81-4.66)e1.53 (0.86-2.73)1.25 (0.45-3.43)3.09 (1.09-8.76)e1.31 (0.42-4.13)

≥75ReferenceReferenceReferenceReferenceReferenceReference
Race/ethnicity

Non-Hispanic WhiteReferenceReferenceReferenceReferenceReferenceReference

Non-Hispanic Black/African American1.37 (0.72-2.63)1.87 (0.98-3.57)0.58 (0.25-1.33)0.64 (0.24-1.69)1.16 (0.46-2.92)1.04 (0.32-3.38)

Hispanic0.60 (0.29-1.27)2.67 (0.49-2.79)0.83 (0.28-2.43)0.26 (0.09-0.71)e1.14 (0.32-4.05)0.47 (0.16-1.39)

Non-Hispanic Asian1.27 (0.51-3.13)2.67 (0.93-7.64)2.11 (0.66-6.70)0.32 (0.07-1.40)1.33 (0.17-10.78)0.47 (0.07-3.31)

Other0.78 (0.34-1.82)1.09 (0.38-3.11)0.98 (0.30-3.23)1.62 (0.30-8.89)1.39 (0.17-11.41)0.47 (0.08-2.62)
Education

Less than high schoolReferenceReferenceReferenceReferenceReferenceReference

High school0.99 (0.41-2.38)0.65 (0.25-1.74)2.37 (0.45-12.57)0.67 (0.13-3.61)2.54 (0.35-18.35)0.48 (0.07-3.46)

Some college1.64 (0.71-3.78)0.96 (0.41-2.24)2.93 (0.59-14.65)0.90 (0.18-4.60)2.61 (0.33-20.58)0.80 (0.12-5.37)

College graduate or more1.94 (0.78-4.81)1.00 (0.41-2.47)6.24 (1.22-32.05)e1.75 (0.40-7.62)2.88 (0.34-24.23)1.76 (0.27-11.38)
Household income (US $)

<20,000ReferenceReferenceReferenceReferenceReferenceReference

20,000-<35,0002.03 (1.00-4.11)e2.41 (1.07-5.40)e1.79 (0.76-4.23)2.08 (0.61-7.07)1.04 (0.31-3.55)0.79 (0.21-2.91)

35,000-<50,0003.40 (1.70-6.82)e2.88 (1.22-6.80)e2.14 (0.94-4.91)2.69 (0.77-9.38)0.66 (0.20-2.16)1.51 (0.38-6.03)

50,000-<75,0003.26 (1.69-6.29)e3.22 (1.56-6.66)e2.20 (1.06-4.56)e6.14 (1.99-18.92)e2.07 (0.34-3.33)1.67 (0.53-5.23)

≥75,0003.55 (1.82-6.90)e3.03 (1.46-6.28)e2.36 (1.05-5.31)e4.20 (1.56-11.28)e0.99 (0.32-3.09)1.59 (0.52-4.85)
Marital status

Married1.10 (0.72-1.69)1.20 (0.80-1.81)0.83 (0.52-1.32)0.88 (0.46-1.67)2.26 (1.06-4.86)e1.09 (0.54-2.20)

Not marriedReferenceReferenceReferenceReferenceReferenceReference
Health insurance type

Employment/privateReferenceReferenceReferenceReferenceReferenceReference

Medicare0.65 (0.38-1.10)0.99 (0.54-1.83)1.19 (0.58-2.43)0.47 (0.16-1.35)0.21 (0.08-0.54)e0.41 (0.13-1.35)

Medicaid0.48 (0.25-0.91)e1.01 (0.49-2.11)0.88 (0.37-2.11)0.83 (0.24-2.90)0.19 (0.06-0.61)e0.36 (0.11-1.21)

Tricare, VAf, IHSg0.41 (0.21-0.80)e1.05 (0.53-2.09)0.61 (0.26-1.44)1.42 (0.39-5.26)0.69 (0.21-2.29)0.89 (0.21-3.78)

Other0.49 (0.27-0.89)e0.88 (0.43-1.79)0.71 (0.29-1.75)0.34 (0.09-1.37)0.20 (0.07-0.58)e0.34 (0.010-1.21)
Usual source of care

Yes1.58 (0.88-2.84)1.58 (0.91-2.76)2.55 (1.21-5.38)e6.17 (2.12-17.99)e0.98 (0.26-3.69)6.23 (1.66-23.39)e

NoReferenceReferenceReferenceReferenceReferenceReference
Number of office visitsin a year

0ReferenceReferenceReferenceReferenceReferenceReference

1-42.05 (0.73-5.77)4.46 (1.49-13.37)e1.98 (0.51-7.60)0.83 (0.26-2.63)2.15 (0.50-9.25)8.25 (1.61-42.18)e

5-92.55 (0.90-7.22)5.91 (1.94-17.97)e2.85 (0.67-12.02)1.18 (0.35-3.97)2.32 (0.52-10.34)7.55 (1.56-36.60)e

aOPPC: online patient-provider communication.

baOR: adjusted odds ratio.

cAdjusted for all the variables in the table.

dEHR: electronic health record.

eP<.05.

fVA: Veterans Affairs.

gIHS: Indian Health Services.

Table 8. Associations of clinical factors with OPPCa among cancer survivors pre–COVID-19 (2017-2019) and during COVID-19 (2020).
FactorsPre–COVID-19 (N=1444), aORb,c (95% CI)During COVID-19 (N=456), aORc (95% CI)


Email/internet (n=1411)Tablet/smartphone (n=1307)EHRd (n=1229)Email/internet (n=446)Tablet/smartphone (n=441)EHR (n=444)
General health status

Excellent/good1.36 (0.87-2.12)0.79 (0.49-1.28)0.81 (0.45-1.48)1.52 (0.64-3.63)1.94 (0.82-4.60)0.84 (0.35-2.00)

Fair/poorReferenceReferenceReferenceReferenceReferenceReference
Chronic condition

Depression1.46 (0.93-2.29)1.43 (0.88-2.32)1.43 (0.80-2.57)0.33 (0.14-0.78)e1.59 (0.55-4.55)0.73 (0.32-1.70)

No depressionReferenceReferenceReferenceReferenceReferenceReference
Mental health (past 2 weeks)

Depression symptoms1.35 (0.69-2.66)1.10 (0.56-2.17)0.87 (0.39-1.92)0.99 (0.24-4.10)0.52 (0.14-2.00)0.41 (0.07-2.29)

No symptomsReferenceReferenceReferenceReferenceReferenceReference

Anxiety symptoms1.23 (0.61-2.48)1.10 (0.54-2.23)1.24 (0.53-2.88)2.21 (0.51-9.61)1.52 (0.29-7.93)2.14 (0.53-8.62)

No symptomsReferenceReferenceReferenceReferenceReferenceReference
Time since diagnosis(years)

<11.56 (0.88-2.77)1.49 (0.81-2.74)1.36 (0.65-2.84)1.26 (0.47-3.40)2.15 (0.69-6.69)0.88 (0.24-3.15)

2-52.02 (1.23-3.33)e1.86 (1.14-3.03)e2.30 (1.29-4.11)e0.97 (0.40-2.39)0.54 (0.18-1.63)1.17 (0.50-2.70)

6-101.21 (0.76-1.92)0.99 (0.60-1.61)1.83 (0.97-3.43)0.47 (0.20-1.09)0.59 (0.26-1.35)0.42 (0.15-1.18)

≥11ReferenceReferenceReferenceReferenceReferenceReference
Cancer type

BreastReferenceReferenceReferenceReferenceReferenceReference

Cervical0.94 (0.40-2.21)0.61 (0.26-1.43)1.28 (0.51-3.22)0.90 (0.26-3.10)0.41 (0.13-1.30)1.58 (0.31-8.22)

Prostate1.01 (0.51-1.97)0.79 (0.41-1.53)0.43 (0.17-1.09)1.17 (0.38-3.57)0.26 (0.09-0.77)e1.65 (0.48-5.69)

Colon1.08 (0.45-2.57)1.47 (0.60-3.59)0.40 (0.10-1.66)1.74 (0.42-7.21)0.87 (0.22-3.45)1.60 (0.36-7.01)

Lung0.41 (0.14-1.20)0.14 (0.04-0.47)e0.26 (0.08-0.86)e1.68 (0.25-11.27)3.21 (0.59-17.42)0.26 (0.02-2.92)

Melanoma0.99 (0.39-2.49)0.41 (0.17-1.00)0.85 (0.31-2.33)0.97 (0.24-3.92)0.39 (0.08-1.98)0.82 (0.18-3.71)

Multiple1.81 (0.97-3.36)0.99 (0.56-1.78)1.18 (0.63-2.22)1.07 (0.32-3.65)0.42 (0.14-1.28)1.14 (0.31-4.20)

Other0.88 (0.48-1.59)0.62 (0.35-1.07)0.72 (0.38-1.36)0.90 (0.32-2.53)0.61 (0.24-1.58)1.26 (0.38-4.18)

aOPPC: online patient-provider communication.

baOR: adjusted odds ratio.

cAdjusted for all the variables in the table.

dEHR: electronic health record.

eP<.05.

Cancer Survivors vs Adults Without a History of Cancer

Among cancer survivors (Tables 6-8) and adults without a history of cancer (Multimedia Appendix 1), those with a usual source of care were 2-6 times as likely to use OPPC than those without a source pre–COVID-19 and during COVID-19. Among those without a history of cancer in both time periods, those who were more educated were 2-6 times and those who reported depression were 1.5-2 times as likely to use OPPC (Multimedia Appendix 1). However, among cancer survivors, we did not observe associations with education and found that depression was inversely associated with OPPC.


Principal Findings

Using nationally representative survey data in the United States from 2017 to 2020, we identified that having a usual source of care or health care office visits is strongly associated with 3 types of OPPC, and different sociodemographic and clinical characteristics were associated with OPPC among cancer survivors and adults without a history of cancer during the pre–COVID-19 and COVID-19 periods. Cancer survivors were more likely to use email/internet to communicate with providers than those without a history of cancer prior to the COVID-19 pandemic, yet no difference was found during the early pandemic. However, OPPC use was higher during COVID-19 than pre–COVID-19 among cancer survivors. During COVID-19, subgroups of cancer survivors were less likely to use OPPC, including the oldest cancer survivors (≥75 years), who were Hispanic, had the lowest income, were unmarried, had no usual source of care or no visits to health providers, had public/no health insurance, or reported having depression. However, a lower education level was associated with lower OPPC among adults without a history of cancer during COVID-19. Our findings identified vulnerable subgroups of cancer survivors who were left behind in OPPC, which is increasingly becoming part of health care [19-21,24].

During COVID-19, but not prior to the pandemic, cancer survivors who were not married or had Medicare, Medicaid, or other health plans, including no insurance, were significantly less likely to use a tablet/smartphone to communicate with providers. Our marital status findings are consistent with prior studies that have found that individuals living with a spouse or partner are more likely to perform healthy behaviors (eg, a higher success rate of quitting tobacco [42,43]). Differences by health insurance could be related to the surge in telehealth use among those with private/employment-based insurance when major insurance companies started reimbursement for telehealth services in early 2020 [44]. The Centers for Medicare and Medicaid Services (CMS) also expanded health care professionals’ role to provide telemedicine to increase telehealth access and its use, including telephone/audio-only or e-visits [45-47]. However, the CMS’s effort to create an enabling environment for telehealth use might not have been enough for cancer survivors with Medicare or Medicaid to increase their use of mobile devices (eg, tablets/smartphones) for communication with providers compared to those with private/employment-based insurance.

Although racial/ethnic differences were not observed among cancer survivors prior to COVID-19 in this study and previously [7,31,32], we observed that Hispanic cancer survivors were significantly less likely to have online communications with providers/offices via email/internet than their non-Hispanic White counterparts during COVID-19. Early in the pandemic, Hispanic populations had higher rates of COVID-19–related hospitalization, intensive care unit admission, or in-hospital death [48,49], which could have been related to a higher prevalence of chronic diseases [50] or having more unmet health care needs [51]. In our study, chronic disease prevalence was not significantly different between racial/ethnic groups, but we were unable to account for unmet health care needs, other than lacking a usual source of care, that could have resulted in less use of online tools to communicate with providers.

Before COVID-19, cancer survivors aged ≥75 years were least likely to practice OPPC via email, the internet, a tablet, or a smartphone. This was also observed among adults without a history of cancer in this study, which aligns with the previous literature [28]. Prior studies suggest that adults aged 65 years and older had less interest in exchanging medical information online with providers [52], less frequently used social media for health communication [53], and less frequently used the internet to search for health information [54] compared to younger generations. This could be potentially due to lower eHealth literacy or higher computer stress among the oldest (≥70 years) compared with younger individuals [55-57]. Older individuals have poorer COVID-19 outcomes [58] and a higher level of fear of COVID-19 [59]; hence, their demands for OPPC might have been high to avoid possible exposure during our study period, yet the barriers noted before could have limited their use of OPPC. In addition, low income was significantly associated with lower OPPC among cancer survivors before COVID-19, consistent with low income being strongly associated with low health technology use in the general population [52,55]. Specifically, low-income older adults designated a lack of financial resources as a barrier to technology access and ownership [60]. However, these strong associations with low income in OPPC were less evident among cancer survivors during COVID-19, suggesting that lacking financial resources was less of a barrier to OPPC use in the early COVID-19 period. Because older age and low income have been associated with eHealth activities, including OPPC, further investigations are warranted to confirm whether they remain in the extended COVID-19 period.

Notably, we observed different associations between depression and education with the use of OPPC among cancer survivors compared to adults without a cancer history. In our study, cancer survivors reporting depression as a chronic condition were less likely to use email/internet to communicate with providers than their counterparts during COVID-19. Prior studies either have not found associations [31] or have not assessed the associations of depression with OPPC [7,32]. However, depression was associated with the use of all 3 types of OPPC among adults without a history of cancer pre–COVID-19 and during COVID-19. The differing associations with OPPC among cancer survivors will need to be further investigated to determine whether our findings were specific to conditions in the early COVID-19 period that generated extreme mental distress. In addition, even though less educated adults without a history of cancer were less likely to use OPPC during COVID-19 and pre–COVID-19, these associations were not observed among cancer survivors in our study. In contrast to our findings, 2 prior studies (2003-2008 [31] and 2003-2018 [32]) have reported that highly educated cancer survivors are more likely to email providers [7]. Given the widespread use of email/internet, the education level may impact OPPC use less compared to other factors, such as access or eHealth literacy, that have been found to impact use more recently [55]. Therefore, our findings suggest that education level might not be a barrier to cancer survivors’ use of OPPC.

In this study, 16% of cancer survivors and 36% of US adults without a history of cancer reported no usual source of care, which was consistently associated with lower OPPC use among both cancer survivors and adults without a history of cancer before and during COVID-19. The likelihood of OPPC use among cancer survivors with a usual source of care appeared to be stronger during COVID-19. In addition, visiting the health provider’s office was strongly associated with EHR-based communications during the pandemic. One potential explanation could be that it would have been easier for those who had a usual source of care or recent office visits to connect with providers online than those without, particularly when in-person office visits were extremely limited under the stay-at-home order in 2020. Previous studies have not considered the usual source of care when assessing OPPC among cancer survivors [7,31,32]. However, it has been associated with OPPC in the general population [61]. To increase the usual source of care among cancer survivors, enhancing insurance coverage (eg, Medicaid expansion [51]) will need to be prioritized to improve health care access in underserved populations [62]. In addition, improving the perceived quality of care and physician trust [63,64] could improve health care–seeking behaviors [65,66].

Given that OPPC is a combination of health technology use and health care–seeking behavior, it requires a multifaceted approach to support it among cancer survivors. Prior studies have identified that health technology use is impacted by low digital device ownership, poor internet access, and lack of technical assistance [29,67,68] and health care seeking is lower among racial/ethnic minority populations and those with a poor patient-provider relationship [63,69]. Our study adds to this knowledge base by identifying vulnerable subgroups in OPPC. Interventions to improve OPPC should incorporate comprehensive and consistent health policies to cover diverse televisits (eg, audio-only calls, videoconferences), enhancing eHealth literacy, and increasing access to digital devices. Given that OPPC is technology-based communication, an effort to improve eHealth literacy among the targeted groups (eg, low socioeconomic status) is recommended, along with creating a technology-enabling environment [54]. One example of improving health literacy is the nationwide collaboration of the Adult Basic Education (ABE) network with community health organizations [70,71] by raising awareness of health literacy among ABE-registered low-literate individuals and implementing pilot projects into the targeted population via peers (eg, peer language navigators [72]). In addition, qualitative studies are suggested for a deeper understanding of barriers to and facilitators of OPPC in the vulnerable subgroups identified in this study.

Limitations

This study has some limitations. First, because we used cross-sectional survey data, we could not determine the prospective and longitudinal associations with OPPC. Second, although the data used in this study were high-quality national survey data, they carry inevitable weaknesses originating from self-reporting and the possibilities of reporting bias (eg, communicated with providers via EHRs more than 12 months ago but reported it as within 12 months, intentionally or unintentionally). Third, due to the questionnaire time frame (in the past 12 months), it is possible that our outcome measurements during COVID-19 could have captured respondents’ behaviors before COVID-19. Fourth, the overall response rate of an average 33.0% during the study period could result in selection bias. However, HINTS applied full sampling weights and conducted imputation to minimize nonresponse. Fifth, the COVID-19 sample size was smaller than the pre–COVID-19 sample size (2017-2019) since the year 2020 was the only available data for COVID-19. Further, the HINTS 5 Cycle 4 questionnaires were administered and collected in the first half year of 2020 (February-June). Hence, we need to interpret the findings of this study from the context of the early COVID-19 period.

Conclusion

Our findings suggest that cancer survivors who were older, had no usual source of care or health care office visits, had a low income, had public or no health insurance, were Hispanic, were unmarried, or reported depression were less likely to use OPPC during COVID-19, findings that differed from associations in adults without a history of cancer. As OPPC is increasingly becoming part of health care, we need to continue to evaluate disparities in its use in the extended COVID-19 period. Strategies to increase the use of OPPC include improvement in health policies to cover virtual visits, interventions to enhance eHealth literacy, and community-based or nationwide efforts to expand health technology access. Our findings identify vulnerable subgroups of cancer survivors with lower OPPC who can be targeted through multidimensional interventions to prevent further inequities.

Data Availability

The data for this study are publicly available [73].

Conflicts of Interest

None declared.

Multimedia Appendix 1

Associations of sociodemographic and clinical factors with OPPC among noncancer populations pre–COVID-19 (2017-2019) and during COVID-19 (2020). OPPC: online patient-provider communication.

DOCX File , 32 KB

  1. Jiang S. How does online patient-provider communication heal? Examining the role of patient satisfaction and communication experience in China. Health Commun 2019 Nov 10;34(13):1637-1644. [CrossRef] [Medline]
  2. Kantsiper M, McDonald EL, Geller G, Shockney L, Snyder C, Wolff AC. Transitioning to breast cancer survivorship: perspectives of patients, cancer specialists, and primary care providers. J Gen Intern Med 2009 Nov 18;24 Suppl 2(Suppl 2):S459-S466 [FREE Full text] [CrossRef] [Medline]
  3. Li C, Matthews AK, Dossaji M, Fullam F. The relationship of patient-provider communication on quality of life among African-American and white cancer survivors. J Health Commun 2017 Jul 05;22(7):584-592 [FREE Full text] [CrossRef] [Medline]
  4. Heisler M, Bouknight RR, Hayward RA, Smith DM, Kerr EA. The relative importance of physician communication, participatory decision making, and patient understanding in diabetes self-management. J Gen Intern Med 2002 Apr;17(4):243-252 [FREE Full text] [CrossRef] [Medline]
  5. Burg MA, Adorno G, Lopez EDS, Loerzel V, Stein K, Wallace C, et al. Current unmet needs of cancer survivors: analysis of open-ended responses to the American Cancer Society Study of Cancer Survivors II. Cancer 2015 Feb 15;121(4):623-630 [FREE Full text] [CrossRef] [Medline]
  6. Street RL, Makoul G, Arora NK, Epstein RM. How does communication heal? Pathways linking clinician-patient communication to health outcomes. Patient Educ Couns 2009 Mar;74(3):295-301. [CrossRef] [Medline]
  7. Jiang S, Hong Y, Liu P. Trends of online patient-provider communication among cancer survivors from 2008 to 2017: a digital divide perspective. J Cancer Surviv 2019 Apr;13(2):197-204. [CrossRef] [Medline]
  8. Tarver WL, Menser T, Hesse BW, Johnson TJ, Beckjord E, Ford EW, et al. Growth dynamics of patient-provider internet communication: trend analysis using the Health Information National Trends Survey (2003 to 2013). J Med Internet Res 2018 Mar 29;20(3):e109 [FREE Full text] [CrossRef] [Medline]
  9. Girault A, Ferrua M, Lalloué B, Sicotte C, Fourcade A, Yatim F, et al. Internet-based technologies to improve cancer care coordination: current use and attitudes among cancer patients. Eur J Cancer 2015 Mar;51(4):551-557. [CrossRef] [Medline]
  10. Santana S, Lausen B, Bujnowska-Fedak M, Chronaki C, Kummervold PE, Rasmussen J, et al. Online communication between doctors and patients in Europe: status and perspectives. J Med Internet Res 2010 Jun 15;12(2):e20 [FREE Full text] [CrossRef] [Medline]
  11. Chen G, Wu Q, Jiang H, Zhang H, Peng J, Hu J, et al. Fear of disease progression and psychological stress in cancer patients under the outbreak of COVID-19. Psychooncology 2020 Jul 14;29(9):1395-1398. [CrossRef]
  12. Han J, Zhou F, Zhang L, Su Y, Mao L. Psychological symptoms of cancer survivors during the COVID-19 outbreak: a longitudinal study. Psychooncology 2021 Mar 23;30(3):378-384. [CrossRef] [Medline]
  13. Soriano EC, Perndorfer C, Otto AK, Fenech AL, Siegel SD, Dickson-Witmer D, et al. Psychosocial impact of cancer care disruptions in women with breast cancer during the COVID-19 pandemic. Front Psychol 2021 Jun 14;12:662339 [FREE Full text] [CrossRef] [Medline]
  14. Islam JY, Vidot DC, Camacho-Rivera M. Evaluating mental health–related symptoms among cancer survivors during the COVID-19 pandemic: an analysis of the COVID Impact Survey. JCO Oncol Pract 2021 Sep;17(9):e1258-e1269. [CrossRef]
  15. Young AM, Ashbury FD, Schapira L, Scotté F, Ripamonti CI, Olver IN. Uncertainty upon uncertainty: supportive care for cancer and COVID-19. Support Care Cancer 2020 Sep 2;28(9):4001-4004 [FREE Full text] [CrossRef] [Medline]
  16. Massicotte V, Ivers H, Savard J. COVID-19 pandemic stressors and psychological symptoms in breast cancer patients. Curr Oncol 2021 Jan 08;28(1):294-300 [FREE Full text] [CrossRef] [Medline]
  17. Jacome LS, Deshmukh SK, Thulasiraman P, Holliday NP, Singh S. Impact of COVID-19 pandemic on ovarian cancer management: adjusting to the new normal. CMAR 2021 Jan;13:359-366. [CrossRef]
  18. Shokri T, Lighthall JG. Telemedicine in the era of the COVID-19 pandemic: implications in facial plastic surgery. Facial Plast Surg Aesthet Med 2020 Jun 01;22(3):155-156. [CrossRef] [Medline]
  19. Bokolo AJ. Application of telemedicine and eHealth technology for clinical services in response to COVID‑19 pandemic. Health Technol (Berl) 2021 Jan 14;11(2):359-366 [FREE Full text] [CrossRef] [Medline]
  20. Moazzami B, Razavi-Khorasani N, Dooghaie Moghadam A, Farokhi E, Rezaei N. COVID-19 and telemedicine: immediate action required for maintaining healthcare providers well-being. J Clin Virol 2020 May;126:104345 [FREE Full text] [CrossRef] [Medline]
  21. Vidal-Alaball J, Acosta-Roja R, Pastor Hernández N, Sanchez Luque U, Morrison D, Narejos Pérez S, et al. Telemedicine in the face of the COVID-19 pandemic. Aten Primaria 2020 Jun;52(6):418-422 [FREE Full text] [CrossRef] [Medline]
  22. Rao SS, Loeb AE, Amin RM, Golladay GJ, Levin AS, Thakkar SC. Establishing telemedicine in an academic total joint arthroplasty practice: needs and opportunities highlighted by the COVID-19 pandemic. Arthroplast Today 2020 Sep;6(3):617-622 [FREE Full text] [CrossRef] [Medline]
  23. Novara G, Checcucci E, Crestani A, Abrate A, Esperto F, Pavan N, Research Urology Network (RUN). Telehealth in urology: a systematic review of the literature. How much can telemedicine be useful during and after the COVID-19 pandemic? Eur Urol 2020 Dec;78(6):786-811 [FREE Full text] [CrossRef] [Medline]
  24. Chablani SV, Sabra MM. Thyroid cancer and telemedicine during the COVID-19 pandemic. J Endocr Soc 2021 Jun 01;5(6):bvab059 [FREE Full text] [CrossRef] [Medline]
  25. Chauhan V, Galwankar S, Arquilla B, Garg M, Somma SD, El-Menyar A, et al. Novel coronavirus (COVID-19): leveraging telemedicine to optimize care while minimizing exposures and viral transmission. J Emerg Trauma Shock 2020;13(1):20-24 [FREE Full text] [CrossRef] [Medline]
  26. Aslani N, Garavand A. The role of telemedicine to control CoVID-19. Arch Clin Infect Dis 2020 Mar 30;15(COVID-19):e102949. [CrossRef]
  27. Garfan S, Alamoodi A, Zaidan B, Al-Zobbi M, Hamid RA, Alwan JK, et al. Telehealth utilization during the Covid-19 pandemic: a systematic review. Comput Biol Med 2021 Nov;138:104878 [FREE Full text] [CrossRef] [Medline]
  28. Zeng B, Rivadeneira NA, Wen A, Sarkar U, Khoong EC. The impact of the COVID-19 pandemic on internet use and the use of digital health tools: secondary analysis of the 2020 Health Information National Trends Survey. J Med Internet Res 2022 Sep 19;24(9):e35828 [FREE Full text] [CrossRef] [Medline]
  29. Lama Y, Davidoff AJ, Vanderpool RC, Jensen RE. Telehealth availability and use of related technologies among Medicare-enrolled cancer survivors: cross-sectional findings from the onset of the COVID-19 pandemic. J Med Internet Res 2022 Jan 25;24(1):e34616 [FREE Full text] [CrossRef] [Medline]
  30. Ng BP, Park C. Accessibility of telehealth services during the COVID-19 pandemic: a cross-sectional survey of Medicare beneficiaries. Prev Chronic Dis 2021 Jul 01;18:E65 [FREE Full text] [CrossRef] [Medline]
  31. Chou WS, Liu B, Post S, Hesse B. Health-related internet use among cancer survivors: data from the Health Information National Trends Survey, 2003-2008. J Cancer Surviv 2011 Sep;5(3):263-270. [CrossRef] [Medline]
  32. Fareed N, Swoboda CM, Jonnalagadda P, Huerta TR. Persistent digital divide in health-related internet use among cancer survivors: findings from the Health Information National Trends Survey, 2003-2018. J Cancer Surviv 2021 Feb 15;15(1):87-98 [FREE Full text] [CrossRef] [Medline]
  33. Health Information National Trends Survey. U.S. Department of Health and Human Services.   URL: https://hints.cancer.gov/ [accessed 2023-03-20]
  34. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP, STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Ann Intern Med 2007 Oct 16;147(8):573-577 [FREE Full text] [CrossRef] [Medline]
  35. Survey instruments. U.S. Department of Health and Human Services.   URL: https://hints.cancer.gov/data/survey-instruments.aspx [accessed 2023-04-21]
  36. Health Information National Trends Survey 5 (HINTS 5) cycle 4 methodology report. Westat. 2020.   URL: https://hints.cancer.gov/docs/methodologyreports/HINTS5_Cycle4_MethodologyReport.pdf [accessed 2023-04-21]
  37. Social determinants of health. U.S. Department of Health and Human Services.   URL: https://health.gov/healthypeople/objectives-and-data/social-determinants-health [accessed 2023-04-21]
  38. Cohen SA, Kunicki ZJ, Nash CC, Drohan MM, Greaney ML. Rural-urban differences in caregiver burden due to the COVID-19 pandemic among a national sample of informal caregivers. Gerontol Geriatr Med 2021 Jun 17;7:23337214211025124 [FREE Full text] [CrossRef] [Medline]
  39. Bisby MA, Karin E, Scott AJ, Dudeney J, Fisher A, Gandy M, et al. Examining the psychometric properties of brief screening measures of depression and anxiety in chronic pain: the Patient Health Questionnaire 2-item and Generalized Anxiety Disorder 2-item. Pain Pract 2022 Apr 12;22(4):478-486 [FREE Full text] [CrossRef] [Medline]
  40. Perneger TV. What's wrong with Bonferroni adjustments. BMJ 1998 Apr 18;316(7139):1236-1238 [FREE Full text] [CrossRef] [Medline]
  41. Rothman KJ. No adjustments are needed for multiple comparisons. Epidemiology 1990 Jan;1(1):43-46. [Medline]
  42. Homish GG, Leonard KE. Spousal influence on smoking behaviors in a US community sample of newly married couples. Soc Sci Med 2005 Dec;61(12):2557-2567 [FREE Full text] [CrossRef] [Medline]
  43. Jackson SE, Steptoe A, Wardle J. The influence of partner's behavior on health behavior change: the English Longitudinal Study of Ageing. JAMA Intern Med 2015 Mar 01;175(3):385-392. [CrossRef] [Medline]
  44. Telehealth for behavioral health care: billing for telebehavioral health. Health Resources and Services Administration.   URL: https:/​/telehealth.​hhs.gov/​providers/​telehealth-for-behavioral-health/​billing-for-telebehavioral-health/​ [accessed 2023-04-21]
  45. Patel SY, Mehrotra A, Huskamp HA, Uscher-Pines L, Ganguli I, Barnett ML. Trends in outpatient care delivery and telemedicine during the COVID-19 pandemic in the US. JAMA Intern Med 2021 Mar 01;181(3):388-391 [FREE Full text] [CrossRef] [Medline]
  46. Notification of enforcement discretion for telehealth remote communications during the COVID-19 nationwide public health emergency. U.S. Department of Health & Human Services.   URL: https:/​/www.​hhs.gov/​hipaa/​for-professionals/​special-topics/​emergency-preparedness/​notification-enforcement-discretion-telehealth/​index.​html [accessed 2023-04-21]
  47. Verma S. Early impact of CMS expansion Of Medicare telehealth during COVID-19. Health Affairs.   URL: https://www.healthaffairs.org/do/10.1377/forefront.20200715.454789/ [accessed 2023-04-21]
  48. Acosta AM, Garg S, Pham H, Whitaker M, Anglin O, O'Halloran A, et al. Racial and ethnic disparities in rates of COVID-19-associated hospitalization, intensive care unit admission, and in-hospital death in the United States from March 2020 to February 2021. JAMA Netw Open 2021 Oct 01;4(10):e2130479 [FREE Full text] [CrossRef] [Medline]
  49. Nanchal R, Patel D, Guddati AK, Sakhuja A, Meersman M, Dalton D, et al. Outcomes of Covid 19 patients-are Hispanics at greater risk? J Med Virol 2022 Mar 26;94(3):945-950 [FREE Full text] [CrossRef] [Medline]
  50. Tai D, Shah A, Doubeni C, Sia I, Wieland M. The disproportionate impact of COVID-19 on racial and ethnic minorities in the United States. Clin Infect Dis 2021 Feb 16;72(4):703-706 [FREE Full text] [CrossRef] [Medline]
  51. Okoro CA, Zhao G, Fox JB, Eke PI, Greenlund KJ, Town M. Surveillance for health care access and health services use, adults aged 18-64 years - Behavioral Risk Factor Surveillance System, United States, 2014. MMWR Surveill Summ 2017 Feb 24;66(7):1-42 [FREE Full text] [CrossRef] [Medline]
  52. Spooner KK, Salemi JL, Salihu HM, Zoorob RJ. eHealth patient-provider communication in the United States: interest, inequalities, and predictors. J Am Med Inform Assoc 2017 Apr 01;24(e1):e18-e27 [FREE Full text] [CrossRef] [Medline]
  53. Chou WS, Hunt YM, Beckjord EB, Moser RP, Hesse BW. Social media use in the United States: implications for health communication. J Med Internet Res 2009 Nov 27;11(4):e48 [FREE Full text] [CrossRef] [Medline]
  54. Kontos E, Blake KD, Chou WS, Prestin A. Predictors of eHealth usage: insights on the digital divide from the Health Information National Trends Survey 2012. J Med Internet Res 2014 Jul 16;16(7):e172 [FREE Full text] [CrossRef] [Medline]
  55. Arcury TA, Sandberg JC, Melius KP, Quandt SA, Leng X, Latulipe C, et al. Older adult internet use and eHealth literacy. J Appl Gerontol 2020 Feb 24;39(2):141-150 [FREE Full text] [CrossRef] [Medline]
  56. Norman CD, Skinner HA. eHealth literacy: essential skills for consumer health in a networked world. J Med Internet Res 2006 Jun 16;8(2):e9 [FREE Full text] [CrossRef] [Medline]
  57. Sieck CJ, Sheon A, Ancker JS, Castek J, Callahan B, Siefer A. Digital inclusion as a social determinant of health. NPJ Digit Med 2021 Mar 17;4(1):52 [FREE Full text] [CrossRef] [Medline]
  58. Brunello A, Galiano A, Finotto S, Monfardini S, Colloca G, Balducci L, et al. Older cancer patients and COVID-19 outbreak: practical considerations and recommendations. Cancer Med 2020 Dec 21;9(24):9193-9204 [FREE Full text] [CrossRef] [Medline]
  59. Han MFY, Mahendran R, Yu J. Associations between fear of COVID-19, affective symptoms and risk perception among community-dwelling older adults during a COVID-19 lockdown. Front Psychol 2021 Mar 23;12:638831 [FREE Full text] [CrossRef] [Medline]
  60. Choi NG, Dinitto DM. The digital divide among low-income homebound older adults: internet use patterns, eHealth literacy, and attitudes toward computer/Internet use. J Med Internet Res 2013 May 02;15(5):e93 [FREE Full text] [CrossRef] [Medline]
  61. Khoong EC, Rivadeneira NA, Hiatt RA, Sarkar U. The use of technology for communicating with clinicians or seeking health information in a multilingual urban cohort: cross-sectional survey. J Med Internet Res 2020 Apr 06;22(4):e16951 [FREE Full text] [CrossRef] [Medline]
  62. Andersen RM, Rice TH, Kominski GF. Changing the US health care system: Key issues in health services, policy, and management: second edition. Google Books. 2002.   URL: https:/​/books.​google.com/​books?hl=en&lr=&id=fF3IDwAAQBAJ&oi=fnd&pg=PR9&ots=I92_eG12-P&sig=4mnF4DMybNCz6jhpZLmIX81NNe4 [accessed 2023-04-21]
  63. Do YK, Carpenter WR, Spain P, Clark JA, Hamilton RJ, Galanko JA, et al. Race, healthcare access and physician trust among prostate cancer patients. Cancer Causes Control 2010 Jan 24;21(1):31-40 [FREE Full text] [CrossRef] [Medline]
  64. Talcott JA, Spain P, Clark JA, Carpenter WR, Do YK, Hamilton RJ, et al. Hidden barriers between knowledge and behavior: the North Carolina prostate cancer screening and treatment experience. Cancer 2007 Apr 15;109(8):1599-1606 [FREE Full text] [CrossRef] [Medline]
  65. Ajzen I. The theory of planned behavior. Organ Behav Hum Decis Process 1991 Dec;50(2):179-211. [CrossRef]
  66. Oberoi S, Chaudhary N, Patnaik S, Singh A. Understanding health seeking behavior. J Family Med Prim Care 2016;5(2):463-464 [FREE Full text] [CrossRef] [Medline]
  67. Jiang S, Liu PL. Digital divide and internet health information seeking among cancer survivors: a trend analysis from 2011 to 2017. Psychooncology 2020 Jan 22;29(1):61-67. [CrossRef] [Medline]
  68. Morris BB, Rossi B, Fuemmeler B. The role of digital health technology in rural cancer care delivery: a systematic review. J Rural Health 2022 Jun;38(3):493-511 [FREE Full text] [CrossRef] [Medline]
  69. Shaw BR, Han JY, Hawkins RP, Stewart J, McTavish F, Gustafson DH. Doctor-patient relationship as motivation and outcome: examining uses of an interactive cancer communication system. Int J Med Inform 2007 Apr;76(4):274-282. [CrossRef] [Medline]
  70. Hohn MD, Lawrence W, McKinney J, Rosen DJ, Santos MG, Sheppard R, et al. Adult basic education: community health partnerships and health disparities. Health Lit Res Pract 2019 Jul;3(3 Suppl):S1-S7 [FREE Full text] [CrossRef] [Medline]
  71. Erikson M, Smith PD, Sparks SW. Best practices to advance health literacy in a Wisconsin Adult Literacy Coalition. Health Lit Res Pract 2019 Jul;3(3 Suppl):S8-S14 [FREE Full text] [CrossRef] [Medline]
  72. Johnson RM, Shepard L, Van Den Berg R, Ward-Waller C, Smith P, Weiss BD. A novel approach to improve health literacy in immigrant communities. Health Lit Res Pract 2019 Jul;3(3 Suppl):S15-S24 [FREE Full text] [CrossRef] [Medline]
  73. Terms of use. U.S. Department of Health and Human Services.   URL: https://hints.cancer.gov/data/download-data.aspx [accessed 2023-04-21]


ABE: Adult Basic Education
CMS: Centers for Medicare and Medicaid Services
EHR: electronic health record
HINTS: Health Information National Trends Survey
IHS: Indian Health Services
OPPC: Online Patient-Provider Communication
OR: odds ratio
VA: Veterans Affairs


Edited by A Mavragani; submitted 18.11.22; peer-reviewed by YR Hong, R Jensen, S Han; comments to author 16.03.23; revised version received 05.04.23; accepted 17.04.23; published 22.05.23

Copyright

©Jiyeong Kim, Eleni Linos, Debra A Fishman, Melanie S Dove, Jeffrey S Hoch, Theresa H Keegan. Originally published in JMIR Cancer (https://cancer.jmir.org), 22.05.2023.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in JMIR Cancer, is properly cited. The complete bibliographic information, a link to the original publication on https://cancer.jmir.org/, as well as this copyright and license information must be included.